{"date":"2026-09-07","count":12,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4745-2026-09-07-1926-vrgebn","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2026-09-07","time":"19:26:08","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告參加2026年上海轄區上市公司集體接待日暨中報業績說明會","clause":"第12款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2026-09-07 19:26，「代重要子公司合富（中國）醫療科技股份有限公司公告參加2026年上海轄區上市公司集體接待日暨中報業績說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-09-07-1844-17hxk3d","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-09-07","time":"18:44:48","subject":"本公司董事會通過解除經理人競業禁止之限制案","clause":"第21款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-09-07 18:44，「本公司董事會通過解除經理人競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-09-07-1844-gi3647","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-09-07","time":"18:44:12","subject":"公告本公司董事會決議買回庫藏股事宜","clause":"第35款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-09-07 18:44，「公告本公司董事會決議買回庫藏股事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7876-2026-09-07-1812-1vm7kom","company_id":"7876","company":"鼎晉生技","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"18:12:08","subject":"OBI-858新型肉毒桿菌素二期重複劑量安全性臨床試驗分析成功達標","clause":"第8款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：鼎晉生技（7876），2026-09-07 18:12，「OBI-858新型肉毒桿菌素二期重複劑量安全性臨床試驗分析成功達標」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2026-09-07-1720-1yksf68","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"17:20:42","subject":"因應本公司上櫃申請需要委託簽證會計師出具內控專審報告","clause":"第25款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-09-07 17:20，「因應本公司上櫃申請需要委託簽證會計師出具內控專審報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6847-2026-09-07-1630-5pdpa9","company_id":"6847","company":"普瑞博","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"16:30:15","subject":"公告本公司115年第一次現金增資延長特定人繳款期限","clause":"第44款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：普瑞博（6847），2026-09-07 16:30，「公告本公司115年第一次現金增資延長特定人繳款期限」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6621-2026-09-07-1612-1s6ldpn","company_id":"6621","company":"華宇藥","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"16:12:28","subject":"本公司代理發言人、內部稽核主管、財務/會計主管異動","clause":"第11款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：華宇藥（6621），2026-09-07 16:12，「本公司代理發言人、內部稽核主管、財務/會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-09-07-1556-1hekgom","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"15:56:43","subject":"代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥LBS-008透過日本先驅藥品認證(Sakigake Designation)向日本厚生勞動省(MHLW)提交新藥查驗登記申請(NDA)(補充公告)","clause":"第44款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-09-07 15:56，「代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥LBS-008透過日本先驅藥品認證(Sakigake」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-09-07-1454-1dxmmrp","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-09-07","time":"14:54:11","subject":"(補充公告)公告本公司變更向關係人取得使用權資產","clause":"第20款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-09-07 14:54，「(補充公告)公告本公司變更向關係人取得使用權資產」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-09-07-1453-7tm2tm","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-09-07","time":"14:53:28","subject":"代重要子公司保盛藥業股份有限公司公告處分不動產。","clause":"第20款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-09-07 14:53，「代重要子公司保盛藥業股份有限公司公告處分不動產。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-09-07-0906-sxpiq","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-09-07","time":"09:06:39","subject":"代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥8LBS-00透過日本先驅藥品認證(Sakigake Designation)向日本厚生勞動省(MHLW)提交新藥查驗登記申請(NDA)","clause":"第44款","fact_date":"2026-09-07","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-09-07 09:06，「代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥8LBS-00透過日本先驅藥品認證(Sakigake」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2026-09-07-0607-15le396","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2026-09-07","time":"06:07:52","subject":"生華科新藥CX-5461獲美國NCI贊助聯用國際製藥大廠賽諾菲及再生元製藥已上市免疫檢查點抑制劑Cemiplimab治療難治性微衛星穩定型結直腸癌人體試驗已成功收治首位患者。","clause":"第53款","fact_date":"2026-08-19","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2026-09-07 06:07，「生華科新藥CX-5461獲美國NCI贊助聯用國際製藥大廠賽諾菲及再生元製藥已上市免疫檢查點抑制劑Cemiplimab治療」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}